Amy Levin
Förmögenhet: 32 056 $ per 2026-08-31
Förmögenhet: 32 056 $ per 2026-08-31
Amy Levin currently works at Oncolytics Biotech, Inc., as Vice President-Clinical Operations from 2020.
Ms. Levin also formerly worked at Puma Biotechnology, Inc., as Senior Director-Clinical Operations from 2011 to 2020 and Janssen Oncology, Inc., as Director-Clinical Program Leader from 2007 to 2011.
Ms. Levin received her undergraduate degree from The University of Texas at Austin.
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
ONCOLYTICS BIOTECH INC. 0,03 % | 2025-12-10 | 38 253 ( 0,03 % ) | 32 056 $ | 2026-08-31 |
| Företag | Position | Start |
|---|---|---|
| ONCOLYTICS BIOTECH INC. | Teknisk/Vetenskaplig/F&U Direktör | 2020-09-01 |
| Företag | Position | Slut |
|---|---|---|
| PUMA BIOTECHNOLOGY, INC. | Teknisk/Vetenskaplig/F&U Direktör | 2020-08-01 |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Företagsledare/Principal | 2011-12-01 |
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Första gradens relationer
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
| Privata företag | 4 |
|---|---|
Oncolytics Biotech, Inc.
Oncolytics Biotech, Inc. BiotechnologyHealth Technology Discovers and develops pharmaceutical products for the treatment of cancers | Health Technology |
The University of Texas at Austin
The University of Texas at Austin Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Janssen Oncology, Inc.
Janssen Oncology, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceutical products for the treatment of cancer | Health Technology |
Puma Biotechnology, Inc.
Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Välj din utgåva
All finansiell information anpassad till den nationella nivån